Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;2(2):125-48.
doi: 10.1177/1758834009360519.

Predictive and prognostic molecular markers for cancer medicine

Affiliations

Predictive and prognostic molecular markers for cancer medicine

Sunali Mehta et al. Ther Adv Med Oncol. 2010 Mar.

Abstract

Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.

Keywords: biomarker; cancer; microarray; pathology; prognosis; treatment response.

PubMed Disclaimer

References

    1. Abbod M.F., Catto J.W., Linkens D.A., Hamdy F.C. (2007) Application of artificial intelligence to the management of urological cancer. J Urol 178: 1150–1156 - PubMed
    1. Abbott L.H., Michor F. (2006) Mathematical Models of Targeted Cancer Therapy. Br J Cancer 95: 1136–1141 - PMC - PubMed
    1. Abdueva D., Wing M.R., Schaub B., Triche T.J. (2007) Experimental comparison and evaluation of the affymetrix exon and U133plus2 genechip arrays. PLoS One 2: e913–e913 - PMC - PubMed
    1. Acharya C.R., Hsu D.S., Anders C.K., Anguiano A., Salter K.H., Walters K.S., et al. (2008) Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299: 1574–1587 - PubMed
    1. Adjei A.A., Christian M., Ivy P. (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866–1872 - PubMed

LinkOut - more resources